BEIJING, July 10 (Xinhua) -- New Horizon Health, a biotechnology company in China, announced on Friday that it completed a round-E financing of 30 million U.S. dollars.
The company stated that it got the investment from investors such as Rock Springs Capital, OrbiMed, Lilly Asia Ventures (LAV), Cormorant Asset Management, CR-CP Life Science Fund Management, Octagon Capital and Qiming Venture Partners.
"We are excited to make this investment in New Horizon, and we look forward to partnering with them as they bring important new diagnostics to market. We are pleased to invest in such an innovative company that is endeavoring to bring real clinical benefits to millions of people who are at elevated risk of developing colorectal cancer," said Mr. Mark Bussard, general member of Rock Springs Capital which led the investment.
Zhu Yeqing, co-founder and CEO of New Horizon Health, said that the company has been focusing on colorectal cancer screening since its inception seven years ago and it shares the vision of curing and preventing cancer through early detection.
New Horizon Health, established in 2013, has medical testing laboratories in Beijing, Hangzhou, and Guangzhou. It has launched home screening products targeting bowel cancer, cervical cancer, gastric cancer, and lung cancer, and serving more than 3 million customers. (Edited by Hu Pingchao with Xinhua Silk Road, hupingchao@xinhua.org)
A single purchase
